Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03091439 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Patients With Osteomyelitis
A Phase 2 study, sponsored by Allergan.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT03091439 is a Phase 2 study that was terminated before completion, run by Allergan. The registered enrollment target is 1 participants.
The verdict
NCT03091439, a Phase 2 study, was terminated before completion, sponsored by Allergan.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This clinical study will be a multi-center, randomized, open-label, active-controlled, parallel-group study comparing dalbavancin to standard of care (SOC) therapy in osteomyelitis.
Interventions
- DRUG Standard of Care
- DRUG Dalbavancin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2017-05-15 |
| Est. Completion | 2017-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03091439
The ClinicalTrials.gov registry entry for NCT03091439 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard of Care is the first listed.
NCT03091439 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03091439 about?
NCT03091439 is a clinical study titled "Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Patients With Osteomyelitis". This clinical study will be a multi-center, randomized, open-label, active-controlled, parallel-group study comparing dalbavancin to standard of care (SOC) therapy in osteomyelitis.
What is the current status of trial NCT03091439?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2017-05-15. Estimated completion is 2017-08-31.
What interventions are being tested in trial NCT03091439?
The interventions under investigation include: Standard of Care (DRUG), Dalbavancin (DRUG).
Who is sponsoring clinical trial NCT03091439?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.